Clinical stage drug development company focusing on Orphan Drug Diseases. The primary concentration at present for Variant is renal disease, specifically FSGS (Focal segmental glomerulosclerosis) & Alport's Syndrome.

Lead the Finance and Business Planning function through the development of sound financial structures and procedures. Oversee budgeting, reporting and operational performance tracking, as well as accounting oversight. Provide financial guidance to CEO of this media company that provides solutions for the pharmaceutical industry. Member of the Board of Directors & Board Audit Committee.EngagedMedia was acquired by Aptus Health, a wholly-owned susidiary of Merck & Co., in June 2018.

• Attending Networking Events• Researching Industry Leaders• Tracking Industry Trends• Participating in Industry Discussions

Successfully transformed business activities regarding operations, business development and product development for privately-held diagnostic medical supply company.• Negotiated all contracts spanning development deals to operational contracts, raising $6MM in working capital.• Prepared annual budget and made recommendations to executive management. • Partnered with executive team to develop and implement strategic and operational plans.• Performed all cash management activities, business planning functions, budgeting, reporting and operational performance tracking.• Performed ad hoc analyses for senior executives involving internal performance measurements.• Redesigned the IT systems, accounting systems and other functions within the organization.

Analyzed all opportunities to expand business both organically and through acquisition for this specialty pharmaceutical company with industry-leading transdermal expertise with over $200MM in sales.• Created financial models to analyze 25 potential acquisitions of commercially marketed products, development projects and targeted strategic alliances.• Developed prioritization for 15 future internally developed compounds for use in the company’s proprietary transdermal delivery systems.• Performed ad hoc analyses for senior executives involving internal performance measurements and for external communications.

Oversaw financial planning & contracting for fully integrated specialty pharmaceutical company with over $750MM in net sales. Joined as Senior Manager in 1998 and progressively promoted to Executive Director. • Led an 8-member team overseeing financial planning & contracting which grew net sales during my tenure from $13MM to $750MM.• Assisted in turning company with annual net loss of $79MM into $118MM in net income.• Direct budgeting, re-forecasting and long-term planning for company with $1 billion in gross sales and $560MM expense budget.• Provided CFO with company financial performance expectations used for Wall Street analyst guidance, evidenced by the 27 straight quarters of meeting/exceeding analyst expectations.• Provided investor relations support and fielded investor question. • Helped company achieve #6 on Fortune’s Fastest Growing Companies List for three-year period.• Negotiated and re-negotiated contracts with vendors and partners that saved the company in excess of $50MM.• Provided financial analysis and oversight in 6 successful acquisitions or partnerships and assisted in the assimilation of those deals into the corporate structure.• Solved problems in functional area of the company including R&D, Production, Sales & Marketing, Business Development, IT and HR, which resulted in greater efficiencies and retained talent.• Revamped original sales force bonus compensation plan and helped develop subsequent year’s new plan.• Created historical database of company sales force performance statistics and company financial performance statistics.

FAS 125 Static Pool Analysis reconciliation for monthly sub-prime auto loan pools.Assist in Asset Backed Securitization portfolio sales and monitoring.Reviewed underwriting criteria for internally originated loans and priced third party pools of loans.